| Overview |
| bs-5471R-FITC |
| MDM2(Ser186) Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Dog, Cow, Pig, Horse, Chicken, Rabbit, Guinea Pig |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human MDM2 around the phosphorylation site of Ser186 |
| Ser186 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4193 |
| Q00987 |
| Cytoplasm, Nucleus |
| HDMX; hdm2; ACTFS; E3 ubiquitin-protein ligase Mdm2; Double minute 2 protein; Oncoprotein Mdm2; p53-binding protein Mdm2; MDM2 |
| E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz